WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology

    SHANGHAI, China, May 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:  
 WX), a leading pharmaceutical, biotechnology and medical device research
 and development outsourcing company with operations in China and the United
 States, today proudly announced that it has appointed Dr. Peng Wang as Vice
 President of Discovery Biology.
 
     (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
 
     Prior to joining WuXi PharmaTech, Dr. Wang was a research fellow at
 Schering-Plough Research Institute where he worked for 18 years with
 increasing responsibilities. He has extensive experience in discovery
 biology, including target validation research, assay development,
 screening, in vitro and in vivo biological and pharmacological studies, and
 mechanism of action and biomarker research. As a discovery team co-chair
 and biology group leader at Schering-Plough, Dr. Wang made significant
 contributions to the nomination of several development candidates, four of
 which are at various phases of clinical trial.
 
     In his new role as Vice President of Discovery Biology, Dr. Wang will
 oversee the company's growing portfolio of discovery biology service
 offerings. Dr. Wang will report directly to Dr. Ge Li, Chairman and Chief
 Executive Officer of WuXi PharmaTech.
 
     "I am very delighted to welcome Dr. Wang on board at this exciting
 time. Dr. Wang's depth of experience will undoubtedly help the company to
 accelerate the development of our discovery biology services, and
 strengthen our medicinal chemistry and biologics discovery capabilities,"
 commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi
 PharmaTech.
 
     Dr. Wang received his Ph.D. in Biochemistry from the University of
 Tokyo, Japan, and has published numerous original biological research
 articles in the leading and peer-reviewed scientific journals.
 
     About WuXi PharmaTech
 
     WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
 device R&D outsourcing company, with operations in China and the United
 States. As a research-driven and customer-focused company, WuXi PharmaTech
 provides pharmaceutical, biotechnology and medical device companies a broad
 and integrated portfolio of laboratory and manufacturing services
 throughout the drug and medical device R&D process. WuXi PharmaTech's
 services are designed to assist its global partners in shortening the cycle
 and lowering the cost of drug and medical device R&D. For more information,
 please visit: http://www.wuxipharmatech.com .
 
 
For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: pr@pharmatechs.com

SOURCE WuXi PharmaTech

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.